Eleni Lagkadinou

Mainz, RP, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy-Treated People With HIV.

Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy-Treated People With HIV.

Journal: Open forum infectious diseases

Published: October 28, 2025

Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies.

Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 20, 2023

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.

Journal: The Lancet regional health. Western Pacific

Published: September 19, 2022

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.

Journal: Advances in therapy

Published: April 06, 2022

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.

Journal: The New England journal of medicine

Published: March 23, 2022

Clinical development and approval of COVID-19 vaccines.

Clinical development and approval of COVID-19 vaccines.

Journal: Expert review of vaccines

Published: February 14, 2022

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

Journal: The New England journal of medicine

Published: November 09, 2021

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.

Journal: Cancer discovery

Published: October 18, 2021

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.

Journal: Vaccine

Published: September 27, 2021

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.

Journal: The New England journal of medicine

Published: September 15, 2021

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults.

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults.

Journal: Nature communications

Published: August 02, 2021

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.

Journal: Nature medicine

Published: December 28, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026